AI Engines For more Details: Perplexity Kagi Labs You
Anticonvulsant Effects: Phensuximide works by inhibiting the spread of abnormal electrical activity in the brain, thus reducing the occurrence of epileptic seizures. It is specifically effective in treating absence (petit mal) seizures, which are characterized by brief periods of unconsciousness or loss of awareness.
Seizure Control: Phensuximide is indicated for the management of absence seizures, particularly in children. It helps in controlling the frequency and severity of these seizures, thereby improving overall seizure control and quality of life.
Sedation and Central Nervous System Effects: Common side effects of phensuximide may include drowsiness, dizziness, fatigue, and difficulty concentrating. These effects are often mild and transient, but they can impair cognitive and motor function, particularly when starting treatment or adjusting the dosage.
Gastrointestinal Effects: Phensuximide may cause gastrointestinal side effects such as nausea, vomiting, and abdominal discomfort. These effects are usually mild and may improve with continued use or dose adjustment.
Psychiatric Effects: Rarely, phensuximide may cause mood changes, irritability, or behavioral disturbances in some individuals, particularly children. Patients should be monitored for changes in mood or behavior during treatment.
Hypersensitivity Reactions: Allergic reactions to phensuximide, such as rash, itching, or swelling, may occur in some individuals. Severe hypersensitivity reactions, including Stevens-Johnson syndrome or toxic epidermal necrolysis, are rare but can be life-threatening.
Blood Disorders: Phensuximide may rarely cause blood disorders such as leukopenia (reduced white blood cell count) or agranulocytosis (severely reduced white blood cell count), which can increase the risk of infections. Patients should be monitored for signs of infection during treatment.
Liver Toxicity: In rare cases, phensuximide may cause liver toxicity or hepatitis, characterized by symptoms such as jaundice (yellowing of the skin or eyes), abdominal pain, or elevated liver enzymes. Liver function tests should be performed periodically during treatment to monitor for liver-related adverse effects.
Bone Marrow Suppression: Phensuximide may rarely suppress bone marrow function, leading to decreased production of blood cells (aplastic anemia) or other blood disorders. Patients should be monitored for signs of anemia, thrombocytopenia, or other hematologic abnormalities.
Interactions: Phensuximide may interact with other medications, particularly other anticonvulsant drugs, increasing the risk of side effects or altering their effectiveness. Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal supplements.
Rank | Probiotic | Impact |
---|---|---|
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.3 | 0.3 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.2 | -0.2 | |
Allergic Rhinitis (Hay Fever) | 0.2 | 0.2 | |
Allergies | 0.3 | 0.3 | |
Allergy to milk products | 0.2 | -0.2 | |
Alopecia (Hair Loss) | 0.5 | 0.5 | |
Alzheimer's disease | 0.3 | 0.4 | -0.33 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | |
Ankylosing spondylitis | 0.5 | 0.5 | |
Anorexia Nervosa | 0.2 | 0.1 | 1 |
Antiphospholipid syndrome (APS) | 0 | 0 | |
Atrial fibrillation | 0.6 | 0.2 | 2 |
Autism | 0.9 | 0.6 | 0.5 |
Barrett esophagus cancer | 0 | 0 | |
Bipolar Disorder | 0.2 | 0.3 | -0.5 |
Carcinoma | 0.3 | 0.3 | 0 |
Celiac Disease | 0 | 0.3 | 0 |
Cerebral Palsy | 0 | 0 | 0 |
Chronic Fatigue Syndrome | 0.1 | 1.5 | -14 |
Chronic Kidney Disease | 0.2 | 0.4 | -1 |
Chronic Obstructive Pulmonary Disease (COPD) | 0 | 0.3 | 0 |
Chronic Urticaria (Hives) | 0 | 0 | |
Coagulation / Micro clot triggering bacteria | 0.3 | 0 | 0 |
Colorectal Cancer | 0.3 | 0 | 0 |
Constipation | 0 | 0 | |
Coronary artery disease | 0 | 0.3 | 0 |
COVID-19 | 0.5 | 0.7 | -0.4 |
Crohn's Disease | 0.6 | 0.6 | 0 |
deep vein thrombosis | 0 | 0 | |
Depression | 0.8 | 1.3 | -0.63 |
Dermatomyositis | 0 | 0 | |
Eczema | 0 | 0 | |
Endometriosis | 0.6 | 0.6 | |
Epilepsy | 0 | 0.3 | 0 |
Fibromyalgia | 0.5 | 0.6 | -0.2 |
Functional constipation / chronic idiopathic constipation | 0.2 | 0.3 | -0.5 |
gallstone disease (gsd) | 0.3 | 0.3 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0 | |
Generalized anxiety disorder | 0 | 0.3 | 0 |
Glioblastoma | 0 | 0 | |
Gout | 0.3 | -0.3 | |
Graves' disease | 0.2 | 0 | 0 |
Halitosis | 0 | 0 | |
Hashimoto's thyroiditis | 0 | 0 | |
Hidradenitis Suppurativa | 0 | 0 | |
hyperglycemia | 0.3 | -0.3 | |
hypersomnia | 0 | 0 | |
hypertension (High Blood Pressure | 0.3 | 0.3 | 0 |
Hypothyroidism | 0.3 | -0.3 | |
Hypoxia | 0.2 | 0.2 | |
Inflammatory Bowel Disease | 0.3 | 0.9 | -2 |
Insomnia | 0 | 0 | |
Intelligence | 0.3 | 0.3 | |
Intracranial aneurysms | 0.3 | 0.3 | |
Irritable Bowel Syndrome | 0.2 | -0.2 | |
Liver Cirrhosis | 0.6 | 0.3 | 1 |
Long COVID | 1.2 | 0.6 | 1 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 0 | 0 | |
Mast Cell Issues / mastitis | 0 | 0.3 | 0 |
ME/CFS with IBS | 0.1 | 0.6 | -5 |
ME/CFS without IBS | 0 | 0.5 | 0 |
Metabolic Syndrome | 0.6 | 0.6 | 0 |
Mood Disorders | 1.1 | 1.3 | -0.18 |
multiple chemical sensitivity [MCS] | 0 | 0 | 0 |
Multiple Sclerosis | 0.3 | 0.8 | -1.67 |
Multiple system atrophy (MSA) | 0 | 0 | |
Neuropathy (all types) | 0 | 0 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0 | 0.4 | 0 |
NonCeliac Gluten Sensitivity | 0 | 0 | |
Obesity | 0.6 | 0.6 | 0 |
obsessive-compulsive disorder | 0.6 | 0.4 | 0.5 |
Osteoarthritis | 0.2 | 0.2 | |
Osteoporosis | 0 | 0 | |
pancreatic cancer | 0 | 0 | |
Parkinson's Disease | 0.6 | 0.7 | -0.17 |
Polycystic ovary syndrome | 0.3 | 0.3 | |
Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
Premenstrual dysphoric disorder | 0 | 0.2 | 0 |
Psoriasis | 0 | 1 | 0 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.3 | 1 |
Schizophrenia | 0.5 | 0.3 | 0.67 |
scoliosis | 0.3 | 0.3 | |
Sjögren syndrome | 0.3 | 0.3 | 0 |
Sleep Apnea | 0.3 | 0.3 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0 | 0 | |
Stress / posttraumatic stress disorder | 0.2 | 0.3 | -0.5 |
Systemic Lupus Erythematosus | 0.6 | 0 | 0 |
Type 1 Diabetes | 0.3 | 0 | 0 |
Type 2 Diabetes | 0.6 | 0.6 | 0 |
Ulcerative colitis | 0 | 0.5 | 0 |
Unhealthy Ageing | 0.6 | 0.4 | 0.5 |
Vitiligo | 0 | 0.8 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [34.204.176 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.204.176 ]